Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and International Harmonization Project criteria.

Naelle Lombion 1 Philippe Robin 2, 3 Adrian Tempescul 4 Pierre Le Roux 3 Ulrike Schick 5 Gaelle Guillerm 6 Jean Ianotto 3 Christian Berthou 7 Pierre Yves Salaün 3 Ronan Abgral 3
1 Department of Clinical Hematology, Institute of Cancerology and Hematology
2 CHU - BREST - Med Nucléaire - CHRU Brest - Service de médecine nucléaire
3 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
4 LBAI - Lymphocyte B et Auto-immunité
5 LaTIM - Laboratoire de Traitement de l'Information Medicale
6 CHU-Brest-Hemato - CHRU Brest - Service d'Hématologie
7 EA2216 - Immunologie et Pathologie
Abstract : Advanced age is an independent poor prognostic factor of diffuse large B-cell lymphoma. PMitCEBO is an alternative to CHOP to decrease side effects in elderly patients. Many studies have shown prognostic value of an interim FDG PET-CT to predict survival. A recent consensus (ICML, Lugano 2013) has suggested using the 5-point scale Deauville criteria instead of those of the international harmonization project (IHP) to visually assess the response on interim PET. The objective of this study was to evaluate the prognostic value of an interim FDG PET-CT in patients older than 60 with treated DLBCL and to compare IHP and 5-PS Deauville visual interpretation to predict survival.
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02042738
Contributor : Ghislaine Calvez <>
Submitted on : Wednesday, February 20, 2019 - 3:34:27 PM
Last modification on : Thursday, February 21, 2019 - 1:31:10 AM

Identifiers

  • HAL Id : hal-02042738, version 1
  • PUBMED : 27901328

Collections

UNIV-BREST | GETBO | IMMUNO | LATIM | IBSAM

Citation

Naelle Lombion, Philippe Robin, Adrian Tempescul, Pierre Le Roux, Ulrike Schick, et al.. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and International Harmonization Project criteria.. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutic, 2016. ⟨hal-02042738⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

19

Contact

Informations

CCSD